Reprint

Innovations in the Integrated Management of Breast Cancer

Edited by
April 2022
278 pages
  • ISBN978-3-0365-3802-0 (Hardback)
  • ISBN978-3-0365-3801-3 (PDF)

This book is a reprint of the Special Issue Innovations in the Integrated Management of Breast Cancer that was published in

Medicine & Pharmacology
Public Health & Healthcare
Summary

Breast cancer is acknowledged as an international priority in healthcare. It is currently the most common cancer in women worldwide, with demographic trends indicating a continuous increase in incidence. Over the years, increasing efforts and resources have been devoted to the search for a systematic and optimized strategy in breast cancer diagnosis and treatment. Today, the Breast Unit model is considered the gold standard in order to ensure optimal patient-centered and research-based clinical services through multidisciplinary and integrated management.Surgical treatment has gradually evolved toward less aggressive approaches with the adoption of new therapeutic strategies. The evolution of evidence-based guidelines in such leading disciplines as radiation and medical oncology has led to a steady improvement in survival rates. This Special Issue will highlight innovations in the integrated management of breast cancer, their potential advantages, and the many open issues that still need to be properly defined and addressed.

Format
  • Hardback
License
© 2022 by the authors; CC BY-NC-ND license
Keywords
metastatic breast cancer; breast surgery; immune system; metabolic derangements; precision medicine; integrated therapies; advanced breast cancer; mTOR inhibitor; CDK4/6 inhibitor; endocrine resistance; breast cancer; pregnancy; chemotherapy; tailoring; personalization; breast cancer; DataMart; real world data; predictive model; healthcare; breast cancer; breast-conserving surgery; non-palpable breast lesions; image-guided localization; preoperative breast localization; breast ultrasound; breast cancer; large database; standardized data collection; networks; breast cancer; nipple-sparing mastectomy; immediate breast reconstruction; acellular dermal matrix (ADM); aesthetic and oncological outcomes; quality of life; rare breast cancer; osteoclast-like giant cells; gene profiling; Oncotype Dx; adjuvant treatment; neoadjuvant chemotherapy; sentinel lymph node; breast cancer; systemic treatment; locally advanced breast cancer; mini-invasive treatment; metastatic breast cancer; liver metastases; hepatic surgery; personalized medicine; sarcopenia; physical performance; frailty; older cancer patients; clinical trial; patient enrollment; artificial intelligence; machine learning; breast cancer; lung cancer; oncology; web app; personalized medicine; breast cancer; conventional CT and CT angiography; DIEP flap planning; breast cancer; neoadjuvant chemotherapy; multidisciplinary treatment; evidence-based medicine; personalized treatment; oncological outcomes; patient quality of life; breast cancer; normal breast; breast pathology; hormone receptor; hormone expression; breast cancer; lymphedema; lymphaticovenous anastomosis; vascularized lymph node transfer; lymphatic microsurgery; radiotherapy; oligometastatic breast cancer; locoregional therapy; CDK4/6 inhibitors; multidisciplinary; breast cancer; AMH; ovarian reserve; chemotherapy; pregnancy desire; subtypes breast cancer; miRNAs; breast cancer treatment; chemotherapy; integrated therapies; next-generation-sequencing; target therapy; precision medicine; personalized medicine; breast cancer; old age; breast-conserving surgery; radiotherapy; survival; vitamin D; breast cancer; ductal breast cancer; in situ breast cancer; lobular breast cancer; histology; n/a